Takeda entered into an agreement with Amag to exclusively market Feraheme for all therapeutic applications in Canada.
Amag will receive a milestone payment of $3m, upon the first commercial sale of Feraheme in Canada.
Amag interim president and CEO Frank E Thomas said the approval by the agency is key milestone for the company and would bolster its efforts in expansion.
"To that end, we have marketing applications for ferumoxytol to treat IDA in adult CKD patients currently under review in other regions, including Europe," Thomas added.